Replies to post #123887 on PharmaCyte Biotech Inc (PMCB)

[livendi]

it doesnt matter pink if ind for pc is never submitted,altime lows speaks volumes,1s are coming fast.who would have dreamed we would be this low after passing the 10 fda tests on our identical batches.great job kw,thanks,for nothing ,karma is a bitch

[Redoocs]

Apex says, cut and dry this company is a scam and will never file an IND.

Also, Apey says, Free The Puppies.

[DragonBear]

New investors, many times it’s been said

and will continued to be said...

that PharmaCyte’s PI, world renowned oncologist, Dr. Manuel Hidalgo, never “presents” PharmaCyte’s CiaB PC therapy as being an “emerging” therapy in pancreatic cancer medicine

Because he doesn't.

Well, that’s simply because he needs to see consistent findings or evidence first

Yet it doesn't prevent Hidalgo to throw out "IFs", and "could" in a Kenny PR pump.

Neither has Hidalgo required CT results when discussing Emerging Therapies. In a 2018 article discussing the role of stem cells in pancreatic cancer, he referenced it as a potential emerging area:

Since CSCs are resistant to traditional therapies including gemcitabine chemotherapy and radiotherapy [61,62], targeting the signaling pathways (Hedgehog, NANOG, STAT3) that drive cancer cell stemness represent a strategy against CSCs.

No drugs were mentioned. None were present at the time in CTs. He frequently mentions various targeted pathways, and immunotherapy targets, as emerging therapies. But he does not mention CIABs or other local drug delivery as "emerging". No need to mention an antiquated therapy idea from 20 yrs ago. DOA.

It has NOTHING to do with his credibility.

Neither does acting as a paid consultant. Stating a couple of generalities in Kenny PR pumps, before collecting his fee.

There you have it...cut and dry.

Yep, complete with the important "IF"

If this endpoint is met,

Is Hidalgo suppose to trash the Kenny Wonder Treatment in a Kenny PR pump, and then stick out his paw to be paid? Or did he suddenly have a memory lapse that Ifosfamide has previously failed in 2nd line patients? So which one is it?

IND submission underway!

Slow internet connection to the FDA?

Patience

Another 6 yrs ought to do ... sumpthin.